Rigel Pharmaceuticals (RIGL) Cost of Revenue (2018 - 2026)

Rigel Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 4.47% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 5.77% decrease from a year earlier, with the FY2025 full-year figure at $19.6 million, up 5.22% from the prior year.
• Cost of Revenue fell to $4.6 million in Q1 2026 per RIGL's latest filing, from $6.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $8.0 million in Q3 2024 and bottomed at $121000.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $2.8 million (2024), against an average of $3.0 million.
• Across the five-year window, Cost of Revenue sank 61.71% in 2022 and jumped 1008.19% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $342000.0 in 2022, then soared by 1008.19% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then advanced by 2.87% to $6.0 million in 2025, then retreated by 22.65% to $4.6 million in 2026.
• Per Business Quant, the three latest RIGL Cost of Revenue figures stand at $4.6 million (Q1 2026), $6.0 million (Q4 2025), and $4.8 million (Q3 2025).